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ABSTRACT
Objectives: HIV-positive women are at increased risk of HPV infection and cervical cancer. European and national guidelines 
advise yearly screening for cervical cancer, however due to the lack of a central registration of HIV infected persons there 
is a gap in offering such care through general healthcare services in many countries, including Poland. 
Material and methods: In response to the above limitations, integrated gynaecological care (IGC) was established at the 
HIV Out-Patient Clinic in Warsaw. We analysed data from January 2007 to May 2014. Logistic regression models were used 
to identify factors associated with not using IGC by patients.
Results: Two hundred and forty women were registered in the observation period:59.6% infected through sexual contact, 
18.7% through IDUs, 19.2 % through unknown causes and 2.5% by other (two were vertically infected). The median follow-up 
time was 2.35 (IQR 0.9–4.5) years and 78.3% were on combination antiretroviral therapy (cART). In total 145 of the women 
(60.4%) used IGC, from 72.1% of those registered in 2007 to 27.3% registered in 2014. There were in total 1075 gynaeco-
logical visits and 254 cervical cytology tests performed. Seventy-five (51.7%) women were tested for HPV infection. Fac-
tors decreasing the odds of not using IGC identified by multivariate regression models were being on cART (OR 0.25 [IQR: 
0.10–0.59]; p = 0.003) and longer time of observation (0.69 [0.58–0.83]; p = 0.0001). 
Conclusions: The utilisation of IGC was very high, but with a delay in commencing the IGC. Women on cART and with 
longer periods of follow-up had lower odds of not using IGC. A screening approach for women not yet on cART, or newly 
registered in the clinics, needs special attention. 
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INTRODUCTION
Screening for human papilloma virus (HPV) infection is 
the most effective method of reducing both the incidence of 
and mortality from cervical cancer [1]. HIV-positive women 
are at increased risk of acquiring HPV and of the HPV infection 
and persistency of HPV infection, especially with high-risk 
HPV [2, 3]. As a consequence, this group of women presents 
a five to six times higher risk of cervical cancer [4, 5]. There-
fore European and national guidelines recommend more 
frequent and age independent screening for cervical cancer 
among HIV positive women [6, 7]. However, due to the lack of 
central registration of HIV infected persons, there is a gap in 
offering such screening through general healthcare services 
in many countries, including Poland. At the same time due 
to the stigma and discrimination HIV-positive women face 
and their fear of the disclosure of their HIV status, they do not 
inform their gynaecologist about their serostatus [8, 9]. Some 
sub-groups of women, such as those who inject drugs or 
those living with two or more children may present a worse 
adherence to both HIV and gynaecological care [10, 11]. 
In Poland during the early period of the HIV epidemic, 
both stigmatisation of HIV persons and infection transmission 
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through injecting drugs were common. In addition, there 
was a high rate of unplanned pregnancies among women 
with HIV and preventing vertical HIV transmission required 
strict follow-up [12]. Due to the above reasons and as a result 
of collaboration between gynaecologists and infectious 
disease specialists, the HIV Out-Patient Clinic in Warsaw 
introduced gynaecological care as part of its HIV services 
in the early 1990s. 
Responding to the increasing interest in the effective-
ness of integrating gynaecological care (IGC) in HIV clinics 
and the barriers to cervical cancer screening we have inves-
tigated the utilisation of gynaecological consultation and 
screening at the HIV Out-Patient Clinic in Warsaw.
MATERIAL AND METHODS
The IGC program was established in 1994 and consisted 
of free-of-charge gynaecological consultations and cervical 
cancer screening, made available without restrictions. Two 
trained gynaecologists were available twice weekly at the 
HIV clinic, which also provided a gynaecological cabinet 
equipped with colposcopy and diagnostic tests. Although 
the IGC was established in 1994, gynaecological visits have 
only been routinely registered in the electronic database since 
2007. Therefore, we only analysed data from January 2007 un-
til May 2014. The demographic characteristics and medical 
records were exported from the Polish Observational Cohort 
of HIV/AIDS Patients (POLCA) database. POLCA is a cohort of 
patients routinely observed at the HIV Out-Patient Clinic in 
Warsaw. Study methods are described elsewhere [13]. 
Use of the IGC was defined as a patient having at least 
one gynaecological consultation at the HIV clinic. 
Cervical cytology was performed according to the stan-
dard methodology. HPV DNA detection and genotyping 
were performed using an HPV Genotypes 14 Real-TM Quant 
kit (Sacace, Italy). The following genotypes were able to be 
detected: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 
68. DNA extraction and amplification steps were done ac-
cording to the manufacturer’s protocol. PCR reactions were 
carried on CFX96 cycler (BioRad, USA). The results obtained 
were analyzed using software provided by the manufacturer. 
In statistical analyses non-parametric tests were used for 
group comparison as appropriate. Univariate and multivari-
ate logistic regression models were used to identify factors 
associated with not using IGC by women registered in the 
clinic. Factors identified as significant (p < 0.1) in univariate 
models were included in a multivariate model. 
A confidence interval (CI) of 95% was accepted. All analy-
ses were performed using SAS version 9.3 (SAS Institute, 
Cary, NC, USA).
Ethical approval for the study had been obtained in 
accordance with Polish regulations; including obtaining 
written informed consent from each participant.
RESULTS
Two hundred and forty women were registered in the 
HIV clinic during the observation period. 143 (59.6%) were 
infected through sexual contacts, 45 (18.7%) through in-
jected drug use and 6 (2.5%) through other (two vertically 
infected) modes of transmission. Forty-six (19.2%) women 
did not disclose the mode of transmission. The median fol-
low-up time was 2.35 (Interquartile range, IQR: 0.9–4.5) years; 
the median age at registration was 30.1 (IQR:26.2–35.1) 
years; and the median baseline lymphocyte CD4+ count 
was 366 (179–545) cells/uL. One hundred and eighty-eight 
(78.3%) women were on cART at the time of data analy-
ses. One hundred and thirteen (48.1%) women had CD4+ 
count below 350 cells/uL at baseline, thus meeting the 
criteria for late presenters. In terms of other co-infections 
44 (18.3) women were anti-HCV positive; 38 (15.8%) were 
anti-HBc total positive; 16 (6.7%) had positive Venereal Di-
sease Research Laboratory (VDRL) tests; but 22 (9.2%) had 
indeterminate VDRL tests. 
In total 145 women (60.4%) used IGC, which ranged 
from 72.1% of those registered in 2007 to 27.3% of those 
registered in 2014 (Fig. 1); with 1079 gynaecological vi-
sits, 252 cervical cytology procedures and 94 HPV evalu-
ations. The median number of gynaecological visits was 
5 (IQR: 2–11) with a minimum one and maximum of 34 visits 
per patient.
The median time from the first visit to the HIV clinic to 
the first gynaecological consultation was 0.4 years (IQR: 0.1– 
–1.3). However, the median time from the first visit to the HIV 
clinic to first cytology result was 0.8 years (0.15–1.95). In total 
126 women, 85.5% of all using IGC, had at least one cytology, 
65 (51.6%) of them more than once. The median number 
of cervical cytology tests per patient was 1 (IQR:1–2). The 
number of cervical cytology tests performed per patient 
was higher in women on antiretroviral therapy, yet with no 
statistical difference (Tab. 1). Seventy-five women (51.7%) 
were tested for HPV infection, but only 17 (22.7%) more 
than once. The median number of HPV tests per patient 
was 1 (IQR:0-1).
In general, women not using IGC were less likely to de-
clare a sexual mode of HIV transmission and more unlikely 
to disclose the mode of infection. A higher proportion of 
women from the IGC group had positive VDRL. Fifty-eight 
women (61%) from the non-IGC group, compared with 
130 women (89.7%) from the IGC group had been on cART 
at the time of our data export (Tab. 2). At the same time, the 
IGC group had a higher median nadir lymphocyte CD4+ 
count and a lower proportion of them had baseline CD4+ 
counts below 350 cells/uL.
In univariate logistic regression models, women had 
significantly increased odds of not using the IGC if they 
had unknown (as compared to sexual) transmission modes 
70
Ginekologia Polska 2018, vol. 89, no. 2
www. journals.viamedica.pl/ginekologia_polska
(2.69 [1.36–5.32; p = 0.04]), unknown baseline (as com-
pared to negative) VDRL (OR 4.79 [1.96–11.68; p = 0.02]) 
and higher nadir lymphocyte CD4+ counts (1.02 [1.01–1.04; 
p < 0.001]). At the same time, a woman’s odds of not using 
the IGC decreased with each additional year in HIV care 
(0.64 [0.54–0.75; p < 0.0001]), with a lymphocyte CD4+ count 
above 350 cells/ul, lower nadir lymphocyte CD4+ counts 
(0.58 [0.34–1.01; p = 0.05]) and being on cART (0.18 [0.09– 
–0.35; p < 0.0001]) (Tab. 2).
In multivariate logistic regression models, adjusted for 
all factors significant in the univariate models, being on cART 
(OR 0.25 [IQR: 0.10–0.59]; p = 0.003) and having a longer 
time in HIV care (0.69 [0.58–0.83]; p = 0.0001) remained the 
only significant factors to decrease a woman’s odds of not 
using IGC (Tab. 3). 
DISCUSSION
The utilisation of IGC in Warsaw HIV Out-Patient Clinic 
was high, with almost two in three women attending at 
least one gynaecological consultation. However, a delay 
in entering gynaecological care was observed with one in 
four patients, who saw the gynaecologists more than a year 
after entering HIV care. In our multivariate analyses the 
odds for not using IGC were 31% lower with each additional 
year of observation and 75% lower for women on cART. 
This suggests that women who are in care for longer peri-
ods might have a better understanding of the necessity of 
gynaecological supervision and be more willing to return 
to the HIV clinic for IGC. A recent Danish populational study 
showed comparable results, with CD4 count > 350 cells/μL 
and HIV RNA < 500 copies/mL being predictors of atten-
dance at the HIV cervical screening program [14]. In the 
Danish study only 2.6% of HIV positive women obtained 
the recommended two cervical cancer screenings in the 
first year from HIV diagnosis. In general, throughout the 
study period, the authors analysed different time intervals, 
with the range of HIV-positive women who followed the 
HIV cervical screening guidelines being from 29% to 46%. 
Compared with the above, a multicentre Catalan study re-
vealed inadequate rates of cervical cancer screening with 
only 50% of HIV positive women reporting that they had 
annual screening [15]. It is worth mentioning that in a pros-
pective study of HPV infection among HIV positive women 
from European countries with a study population of over 
Figure 1. Gynaecological visits registered in integrated care stratified by calendar year
Table 1. Number of cervical cytology tests performed per patient stratified by antiretroviral treatment status
Number of tests 
per patient
All patients Patients not on cART Patients on cART
P value
Frequency (%)
1 61 (48.4) 9 (69.2) 52 (46.0)
0.244
2 30 (23.8) 3 (23.1) 27 (23.9)
3 19 (15.1) 0 (0) 19 (16.8)
4 7 (5.5) 0 (0) 7 (6.2)
5 6 (4.8) 0 (0) 6 (5.3)
6 3 (2.4) 1 (7.7) 2 (1.8)
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Table 2. Baseline characteristics of women using and not using integrated gynaecological care (IGC)
Parameter
Total
N = 240
Women using IGC
N = 145
Women not using 
IGC 
N = 95
P value
N (%)
Mode of HIV transmission
0.02
Sexual contacts 143 (59.6) 94 (64.8) 49 (51.6)
IDU 45 (18.7) 27 (18.6) 18 (18.9)
Other 6 (2.5) 4 (2.8) 2 (2.1)
Unknown 46 (19.2) 20 (13.8) 26 (27.4)
Anty-HCV positive* 44 (18.3) 26 (17.9) 18 (18.9) 0.19
Anty-HBc total positive* 38 (15.8) 21 (14.5) 17 (17.9) 0.11
VDRL positive* 16 (6.7) 8 (5.5) 8 (8.4) < 0.01
On cART 188 (78.3) 130 (89.7) 58 (61.0) < 0.0001
CD4 count < 350 cells/µL on baseline 113 (48.1) 77 (53.1) 36 (40.0) 0.06
Median (IQR)
Age at registration in years* 30.1 (26.2–35.1) 29.1 (26.2–33.7) 31.4 (26.2–35.7) 0.12
Baseline lymphocyte CD4+ count cells/µL* 366 (179–545) 336 (163–539) 384 (222–549) 0.24
Nadir CD4+ count cells/µL (nadir) 260 (142–416) 221 (114–321) 344 (207–462) < 0.001
HIV RNA copies/mL* 5279 (280–514) 7311 (468–56500) 3100 (56–32889) 0.07
Years of follow-up 2.35 (0.9–4.5) 3.2 (1.6–5.4) 1.0 (0.2–2.8) < 0.0001
* at baseline
HIV — human immunodeficiency virus; VDRL — Veneral Disease Research Laboratory
Table 3. Univariate and multivariate logistic regression odds ratios for not using integrated gynaecological care
Parameter Univariate analyses Multivariate analysis
OR 95% CI P value OR 95% CI P value
Mode of infection
Sexual contacts – – – – – –
IDU 1.38 0.69–2.76 0.96 1.12 0.51–2.49 0.90
Other 1.03 0.18–5.85 0.65 1.10 0.14–8.37 0.92
Unknown 2.69 1.36–5.32 0.04 1.55 0.69–3.52 0.47
VDRL negative – – – – – –
VDRL positive 1.86 0.64–5.39 0.78 2.65 0.80–8.80 0.46
VDRL uncertain 2.13 0.87–5.21 0.96 2.23 0.80–6.30 0.67
VDRL unknown 4.79 1.96–11.68 0.02 2.06 0.73–5.81 0.82
On cART 0.18 0.09–0.35 < 0.0001 0.25 0.10–0.59 0.003
Presentation at 
CD4 count < 350 cells/µL
0.58 0.34–1.01 0.05 0.30 0.10–0.91 0.91
Age at registration in years 1.02 0.99–1.05 0.13 – – –
Baseline CD4+ count (cells/µL) 
(per 1 cell increase)
1.00 0.99–1.01 0.93 – – –
Nadir CD4+ (per 10 cells 
increase)
1.02 1.01–1.04 < 0.001 1.00 0.99–1.00 0.95
Years in care (1 per year 
increase)
0.64 0.54–0.75 < 0.0001 0.69 0.58–0.83 0.0001
IDU — injected drug users; CI — confidence interval; OR — odds ratio
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1100 women, only 55.5% provided a second sample after 
6 or more months [3]. 
In our study of women receiving routine care, over half 
the women had two or more cytological tests performed, 
which is still an unsatisfactory result. Especially worrisome is 
the much lower repeatability of HPV screening, as HPV-based 
screening has proved to provide 60 to 70% greater protec-
tion against invasive cervical cancer than cytology [1].
As identified by Konopnicky et al., women with lower 
lymphocyte CD4+ cell counts and who are not yet on cART 
are at higher risk of developing cervical dysplasia. At the 
same time it has been shown that being on cART with im-
mune reconstitution is associated with reducing the risk of 
persistent cervical high-risk human papillomavirus infec-
tion [16]. It is therefore worrying that even in the presence 
of gynaecological services at the HIV clinic these women 
who are not yet on cART are less likely to receive consul-
tations. A special focus should be put on patients enter-
ing care to make sure they understand the importance of 
gynaecological screening and of following the physician’s 
recommendations [17].
Interestingly, according to the baseline characteristics, 
women not using IGC were less likely to declare sexual modes 
of HIV transmission and more likely to declare unknown 
modes of transmission. At the same time, they had higher rates 
of positive VDRL. This could reflect their self-stigmatisation 
and denial of risk behaviours; and this factor underlines the 
need for psychological and social peer support [18]. For this 
group of women, alternative methods, such as self-collected 
samples, should be considered. A recent meta-analysis by 
Arbyn et al. in 2014 shows a growing body of evidence to 
suggest that self-collected samples can be an alternative 
strategy to reach women who are not participating in routine 
cervical cancer screening programmes [19].
It is often presumed that cervical cancer screening 
coverage is satisfactory in Europe, with the consequent 
presumption that special attention is not needed for the 
screening of HIV women. However, data coming from ob-
servational studies in Europe, although scarce, shows that 
barriers to cervical cancer screening still exist, from both the 
patient’s and the health system’s perspectives [14, 15, 20]. 
It is important to note that according to a recently published 
EuroSIDA study of a pan-European longitudinal observa-
tional cohort, cancer screening has a low coverage in both 
Eastern and non-Eastern European countries [21].
Screening approaches for HIV positive women in Poland, 
especially for those not yet on cART or those newly regis-
tered in the HIV clinics, needs special attention. Integrating 
gynaecological services into HIV care is suggested as a way 
of improving coverage for cervical cancer screening; how-
ever, barriers to gynaecological consultations exist even in 
the presence of such integration. 
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